Sevoflurane vs Nitrous Oxide Inhalation at Subanesthetic Concentrations - 11

Substance-Related Disorders Clinical Trial

Official title:

Sevoflurane vs Nitrous Oxide Inhalation at Subanesthetic Concentrations

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00000259
• Other study ID #: NIDA-08391-11
• Secondary ID: R01DA008391R01-0
• Status: Completed
• Phase: N/A
• First received: September 20, 1999
• Last updated: May 26, 2015
• Start date: August 1996
• Est. completion date: November 1997

Study information

• Verified date: May 2015
• Source: University of Chicago
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to conduct experiments to examine subjective and reinforcing effects of nitrous oxide. Mood altering and psychomotor effects will be tested on non-drug abusers and preference procedures will be used to assess reinforcing effects. Comparisons between nitrous oxide, opiates, and benzodiazepine antagonists will be made. To examine sevoflurane versus isoflurane inhalation at subanesthetic concentrations on mood, pain, and psychomotor performance.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: November 1997
• Est. primary completion date: November 1997
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 21 Years to 39 Years
• Eligibility: Please contact site for information.

Study Design

Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)

Related Conditions & MeSH terms

• Disease
• Opioid-Related Disorders
• Substance-Related Disorders

Intervention

Drug:
• 15 % Nitrous oxide

• 0.3 % Sevoflurane

• 30% Nitrous oxide

• 0.6% Sevoflurane

Other:
• Placebo

Locations

Country	Name	City	State
United States	University of Chicago, Anesthesia & Critical Care	Chicago	Illinois

Sponsors (2)

Lead Sponsor	Collaborator
University of Chicago	National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pain intensity	Subjects underwent a 3 min cold immersion test at 30 min of inhalation and then provided response to pain intensity questionnaire	30 min of inhalation	No
Primary	Psychomotor performance	Subjects underwent psychomotor testing at baseline, during inhalation, and during recovery post inhalation	Baseline, 5 min of inhalation; 5, 30, 60 minutes recovery	No
Primary	Cognitive performance	Subject underwent memory, sedation, visual analog, and drug effects testing	Baseline, every 5 min during inhalation, 5, 30, & 60 min during recovery	No